CK-0804 is under clinical development by Cellenkos and currently in Phase I for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase I drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CK-0804’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CK-0804 is under development for the treatment of primary myelofibrosis, myelofibrosis arising from polycythemia vera and essential thrombocythemia. It is administered by intravenous route and comprises of allogeneic cell therapy consisting of T-regulatory cells that exploit the CXCR4/CXCL12 axis and are derived from umbilical cord blood units.
Cellenkos is an early-stage clinical biotechnology company, which focuses on the development of umbilical cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory disorders. The infusion of its lead product candidate, CK0801, leads to the replacement of defective T-REGs and protection of the body from T cell attacks with restoration of immune homeostasis. Cellenkos works in collaboration with the University of Texas MD Anderson Cancer Center to treat a wide range of autoimmune diseases including multiple sclerosis, lupus, rheumatoid arthritis and inflammatory disorders such as Crohn’s disease and aplastic anemia. The company is funded by Golden Meditech Holdings Limited to expand the T-REG technologies. Cellenkos is headquartered in Houston, Texas, the US.
For a complete picture of CK-0804’s drug-specific PTSR and LoA scores, buy the report here.